It should be noted that 4%–7% of NSCLC involves an EML4-ALK fusion kinase that is constitutively activated and shown to promote and maintain the malignant behavior of the cancer cells (Soda et al., 2007; Sasaki et al., 2010). The gene discussed is ALK; the disease is cancer.